Tolcapone in the management of Parkinson's disease

Aging Health

Volumn 2, Issue 5, 2006, Pages 709-720

  Müller, Thomas ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

3 O methyldopa; Catechol O methyltransferase; Homocysteine; Levodopa; Tolcapone

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PERGOLIDE; PLACEBO; RASAGILINE; ROTIGOTINE; SELEGILINE; TOLCAPONE;

ABDOMINAL PAIN; ADJUVANT THERAPY; AKINESIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DEGRADATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ENZYME INHIBITION; HALLUCINATION; HEADACHE; HUMAN; HYPERHIDROSIS; INSOMNIA; LD 50; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MOTOR DYSFUNCTION; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PARKINSON DISEASE; RHABDOMYOLYSIS; URINARY DYSFUNCTION; VOMITING; XEROSTOMIA;

EID: 33750967929     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.2.5.709     Document Type: Article

References (87)

1. Parkison J: An essay on the shaking palsy. Sherwood Neely and Jones, London, UK (1817).
2. Foley P, Riederer P: Pathogenesis and preclinical course of Parkinson's disease. J. Neural Trasm. Suppl. 56, 31-74 (1999).
3. Przuntek H. Müller T, Riederer P: Diagnostic staging of Parkinson's disease: conceptual aspects. J. Neural Transm. 111, 201-216 (2004).
4. Birkmayer W, Hornykiewicz O: The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien. Klin. Wochenschr. 73, 787-788 (1961).
5. Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653-1661 (2002).
6. Müller T. Dopaminergic substitution in Parkinson's disease. Expert Opin. Pharmacother. 3, 1393-1403 (2002).
7. Oertel WH, Wolters E, Sampaio C et al.: Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov. Disord. 21, 343-353 (2006).
8. Whone AL, Watts RL, Stoessl AJ et al.: Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54, 93-101 (2003).
9. Nyholm D: Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin. Pharmacokinet. 45, 109-136 (2006).
10. Hutton JT Metman LV, Chase TN et al.: Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. 16, 459-463 (2001).
11. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284, 1931-1938 (2000).
12. Rascol O, Brooks DJ, Korczyn AD et al.: A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 342, 1484-1491 (2000).
13. Olanow CW, Mytilineou C. Tatton W: Current status of selegiline as a neuroprotective agent in Parkinson's disease. Mov. Disard. 13(Suppl. 1), 55-58 (1998).
14. Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561-566 (2004).
15. Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch. Neurol. 62, 241-248 (2005).
16. Przuntek H, Conrad B, Dichgans J et al.: SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur. J. Neurol. 6, 141-150 (1999).
17. Rascol O, Brooks DJ, Melamed E et al.: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365, 947-954 (2005).
18. Macleod AD, Counsell CE, Ives N et al.: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane. Database. Syst. Rev. CD004898 (2005).
19. Crosby NJ, Deane KH, Clarke CE: Amantadine for dyskinesia in Parkinson's disease. Cochrane. Database. Syst. Rev. CD003467 (2003).
20. Müller T, Kuhn W, Schulte T et al.: Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci. Lett. 339, 25-28 (2003).
21. Müller T, Kuhn W, Przuntek H: Efficacy of budipine and placebo in untreated patients with Parkinson's disease. J. Neural Transm. 112, 1015-1023 (2005).
22. Przuntek H, Müller T: Clinical efficacy of budipine in Parkinson's disease. J. Neural Transm. 56(Suppl.), 75-82 (1999).
23. Przuntek H, Bittkau S, Bliesath H et al.: Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch. Neurol. 59, 803-806 (2002).
24. Verhagen ML, Del Dotto P, van den MP et al.: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease [see comments]. Neurology 50, 1323-1326 (1998).
25. Goetz CG, Poewe W. Rascol O et al.: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov. Disard. 20, 523-539 (2005).
26. Pahwa R, Factor SA, Lyons KE et al.: Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neuralogy 66, 983-995 (2006).
27. Fahn S, Oakes D, Shoulson I et al.: Levodopa and the progression of Parkinson's disease. N. Engl. J. Med. 351. 2498-2508 (2004).
28. Cotzias GC, Papavasiliou PS, Gellene R: Modification of Parkinsonism - chronic treatment with L-dopa. N Engl. J. Med. 280, 337-345 (1969).
29. Müller T, Kuhn W, Przuntek H: Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J. Neural Transm. Gen. Sect. 92, 187-195 (1993).
30. Zhu BT: Catechol-O-methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr. Drug Metab. 3, 321-349 (2002).
31. Ceravolo R, Piccini P, Bailey DL et al.: 18f-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43, 201-207 (2002).
32. Russ H, Müller T, Woitalla D et al.: Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects. Naunyn Schmiedebergs Arch. Pharmacol. 360, 719-720 (1999).
33. Miller JW, Shukitt-Hale B, Villalobos-Molina R etal.: Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol. 20, 55-66 (1997).
34. Müller T, Woitalla D, Schulz D et al.: Tolcapone increases maximum concentration of levodopa. J. Neural Transm. 107, 113-119 (2000).
35. Müller T, Kuhn W: Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Eur. J. Clin. Pharmacol. 62, 447-450 (2006).
36. Olanow CW, Stocchi F: COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications? Neurology 62, S72-S81 (2004).
37. Poewe W: The role of COMT inhibition in the treatment of Parkinson's disease. Neurology 62, S31-S38 (2004).
38. Mannisto PT, Tuomainen P, Tuominen RK: Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br. J. Pharmacol. 105, 569-574 (1992).
39. Zurcher G. Keller HH, Kettler R et al.: Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv. Neurol. 53, 497-503 (1990).
40. Zurcher G, Dingemanse J, Da Prada M: Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv. Neurol. 60, 641-647 (1993).
41. Dingemanse J, Jorga KM, Schmitt M et al.: Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. 57, 508-517 (1995).
42. Jorga KM: Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 50, S31-S38 (1998).
43. Sedek G, Jorga K, Schmitt M et al.: Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol. 20, 531-541 (1997).
44. Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59, 1233-1250 (2000).
45. Borges N: Tolcapone in Parkinson's disease: liver toxicity and clinical efficacy. Expert. Opin. Drug Saf. 4, 69-73 (2005).
46. Napolitano A. Zurcher G, Da Prada M: Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Eur. J. Pharmacol. 273, 215-221 (1995).
47. Zurcher G, Da Prada M, Dingemanse J: Assessment of catechol-O-methyltransferase activity and its inhibition in erythrocytes of animals and humans. Biomed. Chromatogr. 10, 32-36 (1996).
48. Müller T, Erdmann C, Muhlack S et al.: Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/ carbidopa with and without entacapone in patients with Parkinson's disease. J. Neural Thansm. DOI 10.1007/s00702-006-0442-5 (2006) (Epub ahead of print).
49. Waters C: Practical issues with COMT inhibitors in Parkinson's disease. Neurology 55, S57-S59 (2000).
50. Roberts JW, Cora-Locatelli G, Bravi D et al.: Catechol-O-amethyltransferase inhibitor tolcapone prolongs levodopa/ carbidopa action in parkinsonian patients. Neorology 43, 2685-2688 (1993).
51. Napolitano A. Del Dotto P, Petrozzi L et al.: Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease. Clin. Neuropharmacol. 22, 24-29 (1999).
52. Kieburtz K, Hubble J: Benefits of COMT inhibitors in levodopa-treated parkinsonian patients: results of clinical trials. Neurology 55, S42-S45 (2000).
53. Kurth MC, Adler CH, Hilaire MS et al.: Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 48, 81-87 (1997).
54. Hauser RA, Molho E, Shale H et al.: A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De Novo Study Group. Mov. Disord. 13, 643-647 (1998).
55. Dupont E, Burgunder JM, Findley LJ et al.: Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson's Disease Study Group II (TIPS II). Mov. Disord. 12, 928-934 (1997).
56. Factor SA, Molho ES, Feustel PJ et al.: Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin. Neuropharmacol. 24, 295-299 (2001).
57. Onofrj M, Thomas A, Iacono D et al.: Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol. 46, 11-16 (2001).
58. Agid Y, Oertel W, Factor S: Entacapone to tolcapone switch study: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov. Disord. 20, S94 (2005).
59. Agid Y, Destee A. Durif F et al.: Tolcapone, bromocriptine, and Parkinson's disease. French Tolcapone Study Group. Lancet 350, 712-713 (1997).
60. Agid Y, Destee A. Durif F et al.: Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Mov. Disord. 14, 38-44 (1999).
61. Deane KH, Spieker S, Clarke CE: Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease. Cochrane. Database. Syst. Rev. CD004553 (2004).
62. Koller W, Lees A, Doder M et al.: Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov, Disord. 16, 858-866 (2001).
63. Kuhn W, Woitalla D, Gerlach M et al.: Tolcapone and neurotoxicity in Parkinson's disease. Lancet 352, 1313-1314 (1998).
64. Martignoni E, Cosentino M, Ferrari M et al.: Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology 65, 1820-1822 (2005).
65. Colosimo C: The rise and fall of tolcapone. J. Neurol. 246, 880-882 (1999).
66. Jorga KM. Kroodsma JM, Fotteler B et al.: Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin. Pharmacol. Ther. 63, 646-654 (1998).
67. Goetze O, Wieczorek J, Müller T et al.: Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test. Neurosci. Lett. 375, 170-173 (2005).
68. Müller T, Erdmann C, Bremen D et al.: Impact of gastric emptying on levodopa pharmacokinetics in parkinson disease patients, Clin. Neuropharmacol. 29, 61-67 (2006).
69. Müller T, Werne B, Fowler B et al.: Nigral endothelial dysfunction, homocysteine, and Parkinson's disease. Lancet, 354, 126-127 (1999).
70. Müller T, Renger K, Kuhn W: Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Arch. Neurol. 61, 657-660 (2004).
71. Nakaso K, Yasui K, Kowa H et al.: Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J. Neurol. Sci. 207, 19-23 (2003).
72. Müller T, Woitalla D, Kuhn W: Benefit of folic acid supplementation in parkinsonian patients treated with levodopa. J. Neurol. Neurosurg. Psyrhiatry 74, 549 (2003).
73. O'Suilleabhain PE, Sung V. Hernandez C et al.: Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch. Neurol. 61, 865-868 (2004).
74. Ostrem JL, Kang GA, Subramanian I et al.: The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 64, 1482 (2005).
75. Lamberti P, Zoccolella S, Armenise E et al.: Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur. J. Neurol. 12, 365-368 (2005).
76. Valkovic P, Benetin J. Blazicek P et al.: Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat. Disord. 11, 253-256 (2005).
77. Zoccolella S, Lamberti P, Armenise E et al.: Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat. Disord. 11, 131-133 (2005).
78. Huang G, Dragan M, Freeman D et al.: Activation of catechol-O-methyltransferase in astrocytes stimulates homocysteine synthesis and export to neurons. Glia 51, 47-55 (2005).
79. Lee ES, Chen H, Soliman KF et al.: Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26, 361-371 (2005).
80. Isobe C. Murata T, Sato C et al.: Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci. 77, 1836-1843 (2005).
81. Matsubara K, Aoyama K, Suno M et al.: N-methylation underlying Parkinson's disease. Neurotoxicol. Teratol, 24, 593-598 (2002).
82. Rajput AH. Martin W. Saint-Hilaire MH et al.: Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49, 1066-1071 (1997).
83. Rajput AH, Martin W. Saint-Hilaire MH et al.: Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 50, S54-S59 (1998).
84. Baas H, Beiske AG, Ghika J et al.: Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry 63, 421-428 (1997).
85. Adler CH, Singer C, O'Brien C et al.: Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. Neurol. 55, 1089-1095 (1998).
86. Waters CH, Kurth M, Bailey P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 49, 665-671 (1997).
87. Waters CH, Kurth M, Bailey P et al.: Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group. Neurology 50, S39-S45 (1998).